Janux Therapeutics, Inc. (JANX) stock
JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3031% below fair value
$11.37−0.13 (-1.09%)
Close on Nov 13, 2026Market cap $695.13MP/E –Yield –
Janux Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Janux Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -599.3%. For fiscal 2025 it was -1576.7%, against -933.6% the year before. The highest annual figure on record is -779.0% in fiscal 2022.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1576.7% | −643.1 |
| FY2024 | Dec 31, 2024 | -933.6% | −30.7 |
| FY2023 | Dec 31, 2023 | -902.9% | −123.8 |
| FY2022 | Dec 31, 2022 | -779.0% | +126.3 |
| FY2021 | Dec 31, 2021 | -905.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -336.5% | +7828.0 |
| Q2 FY2026 | Jun 30, 2026 | -308.7% | −153.3 |
| Q1 FY2026 | Mar 31, 2026 | -916.5% | +693.8 |
| Q3 FY2025 | Sep 30, 2025 | -352.5% | +303.2 |
| Q3 FY2024 | Sep 30, 2024 | -8164.5% | −7536.2 |
| Q2 FY2024 | Jun 30, 2024 | -155.4% | +1807.6 |
| Q1 FY2024 | Mar 31, 2024 | -1610.3% | −620.0 |
| Q4 FY2023 | Dec 31, 2023 | -655.7% | −13.7 |
| Q3 FY2023 | Sep 30, 2023 | -628.2% | +365.8 |
| Q2 FY2023 | Jun 30, 2023 | -1962.9% | −1233.1 |
| Q1 FY2023 | Mar 31, 2023 | -990.3% | −138.0 |
| Q4 FY2022 | Dec 31, 2022 | -642.0% | +192.7 |
| Q3 FY2022 | Sep 30, 2022 | -994.0% | −53.3 |
| Q2 FY2022 | Jun 30, 2022 | -729.9% | +567.2 |
| Q1 FY2022 | Mar 31, 2022 | -852.2% | −251.2 |
| Q4 FY2021 | Dec 31, 2021 | -834.8% | – |
| Q3 FY2021 | Sep 30, 2021 | -940.7% | – |
| Q2 FY2021 | Jun 30, 2021 | -1297.1% | – |
| Q1 FY2021 | Mar 31, 2021 | -601.1% | – |
See a number that looks wrong?